Eucept Dosage/Direction for Use

Eucept prefilled syringe is available in strengths of 25 mg and 50 mg. Eucept autoinjector is available in strengths of 50 mg.
Posology: Rheumatoid arthritis, Psoriatic arthritis, ankylosing spondylitis and non-radiographic axial spondyloarthritis: 25 mg Eucept administered twice weekly, or 50 mg administered once weekly.
Plaque psoriasis: 25 mg Eucept administered twice weekly, or 50 mg administered once weekly. Alternatively, 50 mg given twice weekly may be used for up to 12 weeks followed, if necessary, by a dose of 25 mg twice weekly or 50 mg once weekly. Treatment with Eucept should continue until remission is achieved, for up to 24 weeks. Continuous therapy beyond 24 weeks may be appropriate for some adult patients. Treatment should be discontinued in patients who show no response after 12 weeks.
If re-treatment with Eucept is indicated, the same guidance on treatment duration should be followed. The dose should be 25 mg twice weekly or 50 mg once weekly. The choice of intermittent or continuous therapy should be based upon physician judgment and individual patient needs. In intermittent therapy, during the period after very first treatment period, the recommended dose of Eucept is 25 mg administered twice weekly or 50 mg administered once weekly.
Special populations: Renal and hepatic impairment: No dose adjustment is required.
Elderly: No dose adjustment is required. Posology and administration are the same as for adults 18-64 years of age.
Paediatric population: Treatment with Eucept should be considered in patients weighing 62.5 kg or more.
Juvenile idiopathic arthritis: The recommended dose of Eucept for patients weighing 62.5 kg or more is 25 mg administered twice weekly or 50 mg administered once weekly. Treatment should be discontinued in patients who show no response after 4 months.
Method of Administration: Eucept is administered by subcutaneous injection.